Silverarc Capital Management, LLC Seres Therapeutics, Inc. Transaction History

Silverarc Capital Management, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$4.95 - $6.09 $702,390 - $864,152	-141,897 Reduced 37.9%	232,525 $1.32 Million
Q4 2022 Feb 14, 2023	BUY	$5.09 - $9.05 $40,358 - $71,757	7,929 Added 2.16%	374,422 $2.1 Million
Q3 2022 Oct 28, 2022	BUY	$3.5 - $7.2 $65,562 - $134,870	18,732 Added 5.39%	366,493 $2.35 Million
Q2 2022 Jul 25, 2022	BUY	$2.7 - $7.62 $56,400 - $159,174	20,889 Added 6.39%	347,761 $1.19 Million
Q1 2022 May 13, 2022	BUY	$6.3 - $8.84 $39,501 - $55,426	6,270 Added 1.96%	326,872 $2.33 Million
Q4 2021 Feb 14, 2022	BUY	$6.02 - $11.43 $275,529 - $523,139	45,769 Added 16.65%	320,602 $2.67 Million
Q3 2021 Nov 15, 2021	BUY	$5.46 - $22.6 $1.15 Million - $4.77 Million	210,918 Added 330.0%	274,833 $1.91 Million
Q2 2021 Aug 16, 2021	SELL	$18.46 - $24.36 $666,129 - $879,030	-36,085 Reduced 36.09%	63,915 $1.52 Million
Q1 2021 May 18, 2021	BUY	$17.66 - $28.92 $1.32 Million - $2.17 Million	75,000 Added 300.0%	100,000 $2.06 Million
Q4 2020 Feb 16, 2021	BUY	$23.25 - $37.73 $581,250 - $943,249	25,000 New	25,000 $613,000

46.3M

119K

466K

Ticker MCRB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 124,072,000
Market Cap $114M
Description
Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company's lead product candidate is the SER-109, an oral microbiome therapeutic candidate that has completed Phase III clinical trial for the ...

Get notified when there are updates to the investment portfolio of Silverarc Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Silverarc Capital Management, LLC with notifications on news.